QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 btig-reiterates-buy-on-embecta-maintains-25-price-target

BTIG analyst Marie Thibault reiterates Embecta (NASDAQ:EMBC) with a Buy and maintains $25 price target.

 embecta-raises-fy2025-adj-eps-guidance-from-270-290-to-290-295-vs-282-est-narrows-fy2025-sales-guidance-from-1073b-1090b-to-1078b-1085b-vs-1083b-est

Fiscal Year 2025 Updated Financial Guidance:For fiscal year 2025, the Company now expects:Dollars in millions, except percentag...

 an-overview-of-embectas-earnings
An Overview of Embecta's Earnings
08/07/2025 15:03:10

 mizuho-maintains-neutral-on-embecta-lowers-price-target-to-12

Mizuho analyst Anthony Petrone maintains Embecta (NASDAQ:EMBC) with a Neutral and lowers the price target from $13 to $12.

 mizuho-maintains-neutral-on-embecta-lowers-price-target-to-13

Mizuho analyst Anthony Petrone maintains Embecta (NASDAQ:EMBC) with a Neutral and lowers the price target from $15 to $13.

 embecta-reaffirms-2025-outlook-with-up-to-109b-revenue-unveils-long-term-plan-to-cut-500m-debt

Embecta Corp. ("embecta"; "The Company") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy i...

 why-is-embecta-stock-falling-on-friday

Embecta reaffirms earnings outlook, trims revenue forecast, and boosts cash flow as restructuring and cost controls offset tari...

 embecta-affirms-fy2025-adj-eps-guidance-of-270-290-vs-280-est-lowers-fy2025-sales-guidance-of-107b-109b-vs-109b-est

Embecta (NASDAQ:EMBC) affirms FY2025 Adj EPS guidance from $2.70-$2.90 to $2.70-$2.90 vs $2.80 analyst estimate. Lowers FY2025 ...

 embecta-q2-adj-eps-070-beats-053-estimate-sales-25900m-beat-25394m-estimate

Embecta (NASDAQ:EMBC) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.53 by 32.0...

 mizuho-initiates-coverage-on-embecta-with-neutral-rating-announces-price-target-of-15

Mizuho analyst Anthony Petrone initiates coverage on Embecta (NASDAQ:EMBC) with a Neutral rating and announces Price Target ...

 becton-dickinson-q1-earnings-revenue-and-eps-beat-lowers-outlook-outlines-intent-to-separate-biosciences-and-diagnostic-solutions-business

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while upd...

 embecta-affirms-fy2025-adj-eps-guidance-from-270-290-to-270-290-vs-281-est-lowers-fy2025-sales-guidance-from-109b-111b-to-107b-109b-vs-110b-est

Embecta (NASDAQ:EMBC) affirms FY2025 Adj EPS guidance from $2.70-2.90 to $2.70-2.90 vs $2.81 analyst estimate. Lowers FY2025 sa...

 embecta-q1-2025-adj-eps-065-beats-044-estimate-sales-261900m-beat-254617m-estimate

Embecta (NASDAQ:EMBC) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.44 by 47.7...

 activist-starboard-value-pushes-becton-dickinson-to-divest-life-sciences-unit

Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION